Jacobs Levy Equity Management, Inc Atreca, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $355,479 - $1.15 Million	-220,795 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $44,355 - $97,211	15,455 Added 7.53%	220,795 $669,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $742,146 - $1.37 Million	151,150 Added 278.93%	205,340 $1.28 Million
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $307,560 - $542,754	39,330 Added 264.67%	54,190 $462,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $57,772 - $85,946	4,444 Added 42.67%	14,860 $228,000
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $135,720 - $178,009	10,416 New	10,416 $168,000
Q3 2020 Nov 16, 2020	SELL	$12.67 - $23.19 $122,924 - $224,989	-9,702 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$12.52 - $23.45 $121,469 - $227,511	9,702 New	9,702 $206,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.